Non-hodgkin lymphoma
LS Evans, BW Hancock - The Lancet, 2003 - thelancet.com
Non-Hodgkin lymphoma is a non-specific term that includes several lymphoproliferative
malignant diseases with different clinical and histological appearances. Here, we …
malignant diseases with different clinical and histological appearances. Here, we …
Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials
L Vidal, A Gafter-Gvili, G Salles… - Journal of the …, 2011 - academic.oup.com
In a previous systematic review and meta-analysis of five randomized controlled trials
comparing rituximab maintenance with no maintenance (observation or rituximab at …
comparing rituximab maintenance with no maintenance (observation or rituximab at …
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3 …
Background Patients with follicular lymphoma can have long survival times, but disease
progression typically occurs 3–5 years after initial treatment. We assessed the potential …
progression typically occurs 3–5 years after initial treatment. We assessed the potential …
[HTML][HTML] ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic …
M Ghielmini, U Vitolo, E Kimby, S Montoto, J Walewski… - Annals of …, 2013 - Elsevier
To complete the existing treatment guidelines for all tumor types, ESMO organizes
consensus conferences to better clarify open issues in each disease. In this setting, a …
consensus conferences to better clarify open issues in each disease. In this setting, a …
[HTML][HTML] Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German Low …
V Jurinovic, B Metzner, M Pfreundschuh… - Biology of Blood and …, 2018 - Elsevier
Patients with follicular lymphoma (FL) and progression of disease (POD) within 24 months
after frontline treatment (POD24) have poor overall survival (OS). The optimal salvage …
after frontline treatment (POD24) have poor overall survival (OS). The optimal salvage …
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up …
Purpose High-dose chemotherapy with peripheral blood progenitor cell (PBPC) autograft is
effective in high-risk lymphoma, particularly with the addition of rituximab; however, it is …
effective in high-risk lymphoma, particularly with the addition of rituximab; however, it is …
Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the …
R Pettengell, N Schmitz, C Gisselbrecht… - Journal of clinical …, 2013 - ascopubs.org
Purpose The objective of this randomized trial was to assess the efficacy and safety of
rituximab as in vivo purging before transplantation and as maintenance treatment …
rituximab as in vivo purging before transplantation and as maintenance treatment …
[HTML][HTML] Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party
S Montoto, P Corradini, M Dreyling, M Ghielmini… - …, 2013 - ncbi.nlm.nih.gov
The aim of this project was to define indications for hematopoietic stem cell transplantation
in follicular lymphoma in Europe. In the absence of evidence-based data, a RAND-modified …
in follicular lymphoma in Europe. In the absence of evidence-based data, a RAND-modified …
Incidence, risk factors and outcome of histological transformation in follicular lymphoma
A Conconi, C Ponzio, C Lobetti‐Bodoni… - British journal of …, 2012 - Wiley Online Library
Histological transformation (HT) into diffuse large B‐cell lymphoma (DLBCL) was
documented in 37 of the 281 (13%; 95% CI, 9–18) follicular lymphoma (FL) patients treated …
documented in 37 of the 281 (13%; 95% CI, 9–18) follicular lymphoma (FL) patients treated …
[HTML][HTML] Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in …
S Le Gouill, S De Guibert, L Planche, P Brice… - …, 2011 - ncbi.nlm.nih.gov
Impact of the use of autologous stem cell transplantation at first relapse both in naïve and
previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS …
previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS …